FGFR1 inhibitor-11

产品编号 T86421Cas号 2157482-40-9

别名

FGFR1inhibitor-11 (compound 5g) 与 FGFR1 结合，其下游 ERK1/2 和 IκBα/NF-κB 信号传导失活可抑制 RANKL 诱导的破骨细胞生成。FGFR1inhibitor-11 有口服活性。

产品编号 T86421Cas号 2157482-40-9

FGFR1inhibitor-11 (compound 5g) 与 FGFR1 结合，其下游 ERK1/2 和 IκBα/NF-κB 信号传导失活可抑制 RANKL 诱导的破骨细胞生成。FGFR1inhibitor-11 有口服活性。

规格	价格	库存	数量
10 mg	询价	10-14周
50 mg	询价	10-14周

大包装 & 定制

加入购物车

实验操作小课堂

联系我们获取更多批次信息

资源下载

TargetMol 的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

生物活性

产品描述	FGFR1 inhibitor-11 (compound 5g) effectively targets and binds to FGFR1, subsequently inhibiting the downstream signaling pathways ERK1/2 and IκBα/NF-κB, which results in the suppression of RANKL-induced osteoclastogenesis. This compound also exhibits oral bioactivity [1].
体外活性	FGFR1 inhibitor-11 (compound 5g): In a Cell Viability Assay with BMDMs, at concentrations of 0, 1.25 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM, 80 μM, and 160 μM, and an incubation time of 48 hours, it exhibited toxicity above 40 μM. In Immunofluorescence with osteoclasts, at concentrations of 0, 2.5 μM, 5 μM, and 10 μM, it significantly and dose-dependently increased the protein level of F-actin. In Real Time qPCR with BMDMs at a 10 μM concentration over 1, 2, and 3 days, it inhibited the mRNA expression levels of the primary osteoclast-specific marker genes (Ctsk, Mmmp9, and others).
体内活性	FGFR1 inhibitor-11（每日两次、口服给药，剂量为15-30 mg/kg）在显著防止小鼠骨质流失方面表现出良好效果，具体体现在骨体积（BV）和总骨矿密度（T-BMD）等指标上 [1]。